Ian Kamaly

Ian Kamaly-Asl is a full time paediatric neurosurgeon based at Royal Manchester Children’s Hospital.  His neurosurgical training was in the North Western Deanery followed by fellowships at Harvard Medical School/Boston Children’s Hospital and The Hospital for Sick Children in Toronto.  He was appointed to his current post in 2005.

Ian is the neurosurgical lead for the paediatric neuro-oncology and paediatric neurovascular services and receives national and international patient referrals for these conditions.



• Society of British Neurological Surgeons – Chairman for CSF Disorders Sub-group
• European Society of Paediatric Neurosurgery – Executive Board Member
• International Society of Pediatric Neurosurgeons – Executive board member and chairman of Ways and Means Committee
• Association of Spina Bifida & Hydrocephalus (Advisory Committee)
• British Paediatric Neurosurgery Group – Chairman of Research Sub Committee

Paediatric brain tumours, vascular disease (arteriovenous malformations (AVMs) cavernous, malformations, moya moya disease), craniosynostosis and positional plagiocephaly.

For his leadership roles, Ian is the current chairman of the British Paediatric Neurosurgical Group, member of the Paediatric Neurosciences Clinical Reference Group and deputy clinical director of the North West Neurosciences Operational Delivery Network.

Ian has various national roles in surgical education including member of the Neurosurgery Specialist Advisory Committee and National lead for simulation in neurosurgery.  He was previously secretary to the Neurosurgical National Selection Board and Training Programme Director of the North Western Deanery.

Ian has an active programme of clinical and basic science research.  He is the principal investigator for several national/international studies and has extensively published in peer reviewed journals, book chapters, national guidelines and presented over 90 papers at national/international meetings.  Ian is a member of the National Cancer Research Institute Children’s Cancer and Leukaemia Clinical Studies Group.